Surgisphere Releases ‘Rapid COVID-19 Triage Tool’ Internationally
As hospitals start to prepare for a surge in confirmed cases of COVID-19, a more pronounced focus will be placed on the appropriate utilization of healthcare resources. Without planning and organization, this surge can lead to delays in care and wasted resources, both of which hurt patients. In conjunction with public health experts, Surgisphere has developed a COVID-19 triage tool that helps prioritize care for patients who are in urgent need of care (https://surgisphere.com/covid-19-triage-tool/).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200319005377/en/
Access a rapid triage tool for front line healthcare professionals to optimize the delivery of timely and effective healthcare to COVID-19 patients. (Graphic: Business Wire)
Surgisphere leveraged its real time global research network to develop this triage tool. Using its #1 ranked machine learning capabilities, Surgisphere identified the clinical signs and symptoms most predictive of poor outcomes. Using patient age, chronic medical conditions such as cardiovascular disease and diabetes, vital signs, and routine physical exam maneuvers, healthcare professionals on the front line can triage a COVID-19 patient in under a minute.
“This smartphone app will help thousands of vulnerable patients. We have already seen healthcare systems around the world struggling to cope with the extensive number of sick patients. Better triaging them to provide vital healthcare to those who need it the most is a top priority. Our data driven approach combined with advanced machine learning has created a solution that can positively impact healthcare delivery,” said Sapan Desai, MD, PhD, MBA, FACS. Dr. Desai is a vascular surgeon and President and Chief Executive Officer of the Surgisphere Corporation.
This triage tool has been prospectively validated and has a 95.5% overall accuracy. 100% of patients who require immediate attention are correctly triaged. This smartphone app can be accessed at https://www.Surgisphere.com. Surgisphere has also created a COVID-19 mortality risk calculator and diagnosis decision support tool, all freely and immediately available to healthcare professionals around the world.
Surgisphere is currently leveraging its coordinated efforts with global health agencies and its own global network of over 1,200 healthcare organizations to facilitate rapid, world-wide deployment of this life-saving tool. The methodology and results associated with this triage tool have been submitted for peer review and publication in a scientific journal.
Surgisphere is a physician-led company dedicated to making the world a better place, a mission that has motivated its growth and progress since its inception in 2008. An ISO 27001:2013 certified corporation in Chicago, Surgisphere has developed leading solutions in healthcare delivery for patients with kidney disease, cardiovascular disease, lymphedema, and other major diseases.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200319005377/en/
Contact information
Sapan Desai
sapan.desai@surgisphere.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 23:30:00 EET | Press release
Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the cornerstone of Australia’s secure military communications since IS-22’s launch in 2012. SES will build a dedicated ground segmen
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 23:05:00 EET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 21:00:00 EET | Press release
Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain and stiffness in the global Phase 3 MANEUVER study
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 20:32:00 EET | Press release
Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112241557/en/ Ricimed - Fabentech Ricimed®, an antidote against one of the most toxic natural substances in the world In addition to supportive care, and in severe situations requiring immediate administration, Ricimed® represents a new therapeutic option for the management of acute ricin intoxication. Ricin, among the most dangerous naturally occurring substances, can cause death within hours or days regardless of the route of exposure, making it a major biological threat for many countries. Having demonstrated its ability to specifically target and neutralize ricin before irreversible damage occurs, Ricimed® is an antibody-based therapy relying on poly
Traxys Group and the Shareholders of Comax2 AB - the holding company of Carbomax AB - sign Share Purchase Agreement to sell 100% interests to Traxys Group12.1.2026 20:20:00 EET | Press release
Traxys S.à.r.l., Investment Aktiebolaget Spiltan and other major shareholders of Comax 2 AB – the holding company of Carbomax AB –are pleased to announce that they have signed a Share Purchase Agreement (SPA) to sell 100% interests to Traxys Group. Carbomax AB is a leading Swedish trading house and industrial operator specializing in ferroalloys, carbon products and briquettes. The transaction aims to strengthen Traxys’ presence in the Scandinavian market and support the region’s transition toward sustainable steel production. Closing of the transaction is expected to occur in the first quarter 2026 following clearance by Swedish authorities, including foreign direct investment and antitrust approvals. Carbomax serves regional steel plants and most of foundries across the Nordics. With its strategic location near Västerås harbor and integrated processing capabilities Carbomax is well-positioned to capitalize on growing demand for green steel and sustainable raw materials. Mark Kristoff
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom